The sales are too small relative to market cap to warrant a bearish stance. Monitor for any unplanned insider sales in the next 30 days; if a pattern of C-suite selling continues above 0.5% of market cap, that would be a more credible signal. For now, the cluster reads as routine diversification.
Price Chart
Executive Summary
Three Immunome insiders sold a total of ~$813K in open-market shares over a one-week window ending July 7, 2026, including the Chief Business Officer, the Chief Medical Officer, and a Director. Director Barchas Isaac alone sold ~$2.4M across two days (July 6–7), making this the dominant insider transaction. At ~0.03% of Immunome's $2.7B market cap, the total sales are trivial in proportional terms, and cluster sales are weak directional signals per the academic literature. The sales are best interpreted as routine portfolio diversification, not a bearish corporate signal.
Key Financial Metrics
Key Facts
- Three insiders sold shares: Director Isaac Barchas ($2.4M), CBO Horn Kinney ($27K + option exercise), CMO Robert Lechleider ($377K)
- Total open-market sales: ~$2.84M; total cluster value after netting derivative exercises: ~$813K
- Sales represent ~0.1% of Immunome's $2.7B market cap
- No insider purchases were filed in this cluster window
- Historical performance on IMNM reports has been poor (avg T+20 P&L -4.1%, 38% win rate)
Financial Impact
$2.84M in total insider open-market sales, or ~0.1% of market cap
Risk Factors
- Additional insider selling in coming weeks could signal deteriorating conviction
- Poor historical model calibration on IMNM (avg T+20 loss of -4.1%) suggests caution on any directional call
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-IMNM-1783634473409 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 1d ago | ANALYST-UPGRADE | $21.58 awaiting T+5 | awaiting T+5 | — | $20.88 (−3.24%) |
Sep 21, 2026 11d ago | ANALYST-UPGRADE | $25.07 $21.68 | ▼ −13.52% | ▼ −13.24% | $20.88 (−16.71%) |
Aug 12, 2026 7w ago | Insider Cluster | $26.42 $28.08 | ▲ +6.28% | ▲ +8.25% | $20.88 (−20.97%) |
Aug 10, 2026 7w ago | Insider Cluster | $26.25 $27.56 | ▲ +4.99% | ▲ +5.39% | $20.88 (−20.46%) |
Jul 9, 2026 12w ago | Insider Cluster | $23.35 $22.20 | ▼ −4.93% | ▼ −4.36% | $20.88 (−10.58%) |
Jul 7, 2026 12w ago | Insider Cluster | $24.01 $22.59 | ▼ −5.91% | ▼ −6.78% | $20.88 (−13.04%) |
Jul 7, 2026 12w ago | Insider Cluster | $24.01 $22.59 | ▼ −5.91% | ▼ −6.78% | $20.88 (−13.04%) |
Jul 3, 2026 13w ago | Insider Cluster | $23.61 $24.17 | ▼ −2.37% | ▼ −1.44% | $20.88 (+11.56%) |
May 28, 2026 18w ago | ANALYST-UPGRADE | $22.54 $19.81 | ▼ −12.11% | ▼ −12.06% | $20.88 (−7.36%) |
May 12, 2026 20w ago | 8-K | $22.20 $19.66 | ▼ −11.44% | ▼ −10.28% | $20.88 (−5.95%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access